Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4 Multicenter, Open-label, Single-arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem to XYWAV for the Treatment of Narcolepsy

Next Previous
X
Search
Trial Profile

A Phase 4 Multicenter, Open-label, Single-arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem to XYWAV for the Treatment of Narcolepsy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JZP 258 (Primary) ; Sodium oxybate
  • Indications Narcolepsy
  • Focus Therapeutic Use
  • Acronyms Segue
  • Sponsors Jazz Pharmaceuticals plc

    • Most Recent Events

    • 10 Apr 2024 According to a Jazz Pharmaceuticals media release, data from this study will be featured at the 76th Annual American Academy of Neurology Meeting (AAN)
    • 31 May 2023 According to a Jazz Pharmaceuticals Inc media release, data from this trial will be presented at the SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies (APSS).
    • 27 Apr 2023 Interim Results (n=24) assessing safety, tolerability, effectiveness, and treatment optimization in participants with narcolepsy transitioning from sodium oxybate to lower-sodium oxybate presented at the 75th Annual Meeting of the American Academy of Neurology 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top